Metabolic and cardiovascular outcomes in a group of adult patients with Turner's syndrome under hormonal replacement therapy

European Journal of Endocrinology

Volumn 164, Issue 5, 2011, Pages 819-826

  Giordano, Roberta ^a   Forno, Daniela ^a   Lanfranco, Fabio ^b   Manieri, Chiara ^b   Ghizzoni, Lucia ^b   Ghigo, Ezio ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GLUCOSE; INSULIN; LIPID; MEDROXYPROGESTERONE; NOMEGESTROL ACETATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ESTROGEN BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; METABOLIC DISORDER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; TURNER SYNDROME; WAIST CIRCUMFERENCE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT TOOL; HOMEOSTATIC MODEL ASSESSMENT INDEX; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; ESTROGEN THERAPY; METABOLISM; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN RESISTANCE; OBESITY; TREATMENT OUTCOME; TURNER SYNDROME; WAIST CIRCUMFERENCE;

EID: 79955526336     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0002     Document Type: Article

References (39)

1. Gravholt CH. Epidemiological, endocrine and metabolic features in Turner syndrome. European Journal of Endocrinology 2004 151 657-687. (doi:10.1530/eje.0.1510657)
2. Turner HH. A syndrome of infantilism, congenital webbed neck and cubitus valgus. Endocrinology 1938 23 566-574. (doi:10.1210/endo-23-5-566)
3. Price WH, Clayton JF & Collyer S. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. Journal of Epidemiology and Community Health 1986 40 97-102. (doi:10.1136/jech.40.2.97)
4. Gravholt CH, Juul S & Naeraa RW. Morbidity in Turner syndrome. Journal of Clinical Epidemiology 1998 51 147-158. (doi:10.1016/S0895-4356(97) 00237-0)
5. Stochholm K, Juul S & Juel K. Prevalence, incidence, diagnostic delay, and mortality in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2006 91 3897-3902. (doi:10.1210/jc.2006-0558)
6. Schoemaker MJ, Swerdlow AJ & Higgins CD. Mortality in women with Turner syndrome in Great Britain: a national cohort study. Journal of Clinical Endocrinology and Metabolism 2008 93 4735-4742. (doi:10.1210/jc.2008-1049)
7. Nathwani NC, Unwin R & Brook CG. Blood pressure and Turner syndrome. Clinical Endocrinology 2000 52 363-370. (doi:10.1046/j.1365-2265.2000.00960.x)
8. Stoppoloni G, Prisco F & Alfano C. Characteristics of insulin resistance in Turner syndrome. Diabetes and Metabolism 1990 16 267-271. (Pubitemid 20333945)
9. Caprio S, Boulware S & Diamond M. Insulin resistance: an early metabolic defect of Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1991 72 832-836. (doi:10.1210/jcem-72-4-832)
10. Gravholt CH, Naeraa RW & Nyholm B. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner syndrome: the impact of sex hormone replacement. Diabetes Care 1998 21 1062-1070. (doi:10.2337/diacare.21.7.1062)
11. Van PL, Bakalov VK & Bondy CA. Monosomy for the X-chromosome is associated with an atherogenic lipid profile. Journal of Clinical Endocrinology and Metabolism 2006 91 2867-2870. (doi:10.1210/jc.2006-0503)
12. Bondy CA. Care of girls and women with Turner syndrome: A Guideline of the Turner Syndrome Study Group. Journal of Clinical Endocrinology and Metabolism 2007 92 10-25. (doi:10.1210/jc.2006-1374)
13. Hulley S, Grady D & Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 280 605-613. (doi:10.1001/jama.280.7.605)
14. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321-333. (doi:10.1001/jama.288.3. 321)
15. Turgeon JL, CarrMC & Maki PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: insights from basic science and clinical studies. Endocrine Reviews 2006 27 575-605. (doi:10.1210/er.2005-0020)
16. Gravholt CH & Weis Naeraa R. Reference values for body proportions and body composition in adult women with Ullrich - Turner syndrome. American Journal of Medical Genetics 1997 72 403-408. (doi:10.1002/(SICI)1096- 8628(19971112)72:4〈403::AID-AJMG6〉3.0.CO;2-R)
17. Grundy SM, Cleeman JI & Daniels SR. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005 112 2735-2752. (doi:10.1161/CIRCULATIONAHA.105.169404)
18. Mancia G, Sega R & Bravi C. Ambulatory blood pressure normality: results from the PAMELA Study. Journal of Hypertension 1995 13 1377-1390. (doi:10.1097/00004872-199512000-00003)
19. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O'Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B & Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2007 25 1105-1187. (doi:10.1097/HJH.0b013e3281fc975a)
20. Nelder JA. A User's Guide to the Evaluation of Statistical Packages and Systems. International Statistical Review 1974 42 291-298. (doi:10.2307/1402986)
21. Gravholt CH, Naeraa RW & Fisker S. Body composition and physical fitness are major determinants of the growth hormone-insulin-like growth factor axis aberrations in adult Turner's syndrome, with important modulations by treatment with 17betaestradiol. Journal of Clinical Endocrinology and Metabolism 1997 82 2570-2577. (doi:10.1210/jc.82.8.2570)
22. Espeland MA, Stefanick ML & Kritz-Silverstein D. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. Journal of Clinical Endocrinology and Metabolism 1997 82 1549-1556. (doi:10.1210/jc.82.5. 1549)
23. Elsheikh M, Bird R & Casadei B. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 614-618. (doi:10.1210/jc.85.2. 614)
24. Brussaard HE, Gevers-Leuven JA & Frolich M. Short-term oestrogen replacement therapy improves insulin resistance, lipids, and fibrinolysis in postmenopausal women with NIDDM. Diabetologia 1997 40 843-849. (doi:10.1007/s001250050758)
25. Godsland IF. Oestrogens and insulin secretion. Diabetologia 2005 48 2213-2220. (doi:10.1007/s00125-005-1930-0)
26. Ross JL, Feuillan P, Long LM, Kowal K, Kushner H & Cutler GB Jr. Lipid abnormalities in Turner syndrome. Journal of Pediatrics 1995 126 242-245. (doi:10.1016/S0022-3476(95)70551-1)
27. Cooley M, Bakalov V & Bondy CA. Lipid profiles in women with 45,X vs 46,XX primary ovarian failure. Journal of the American Medical Association 2003 290 2127-2128. (doi:10.1001/jama.290.16.2127)
28. Walsh BW, Schiff I & Rosner B. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. New England Journal of Medicine 1991 325 1196-1204. (doi:10.1056/ NEJM199110243251702)
29. Sacks FM, Gerhard M & Walsh BW. Sex hormones, lipoproteins, and vascular reactivity. Current Opinion in Lipidology 1995 6 161-166. (doi:10.1097/00041433-199506000-00008)
30. Writing Group for the PEPI Trial. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women. Journal of the American Medical Association 1995 273 199-208. (doi:10.1001/jama.273.3.199)
31. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974 to 2000. Fertility and Sterility 2001 75 898-915. (doi:10.1016/S0015-0282(01)01699-5)
32. Kornhauser C, Malacara JM & Garay ME. The effect of hormone replacement therapy on blood pressure and cardiovascular risk factors in menopausal women with moderate hypertension. Journal of Human Hypertension 1997 11 405-411. (doi:10.1038/sj.jhh.1000420)
33. Mortensen KH, Hansen KW, Erlandsen M, Christiansen JS & Gravholt CH. Ambulatory arterial stiffness index in Turner syndrome: the impact of sex hormone replacement therapy. Hormone Research 2009 72 184-189. (doi:10.1159/000232495)
34. Cheng KS, Mikhailidis DÀ, Hamilton G & Seifalian AM. A review of carotid and femoral intima - media thickness as an indicator of the presence of vascular disease and cardiovascular risk factors. Cardiovascular Research 2002 54 528-538. (doi:10.1016/S0008-6363(01)00551-X)
35. Ostberg JE, Donald AE, Halcox JP, Storry C, McCarthy C & Conway GS. Vasculopathy in Turner syndrome: arterial dilatation and intimal thickening without endothelial dysfunction. Journal of Clinical Endocrinology and Metabolism 2005 90 5161-5166. (doi:10.1210/jc.2005-0677)
36. Ostberg JE, Storry C & Donald AE. A dose - response study of hormone replacement in young hypogonadal women: effects on intima - media thickness and metabolism. Clinical Endocrinology 2007 66 557-564. (doi:10.1111/j.1365-2265. 2007.02772.x)
37. Bush DE, Jones CE & Bass KM. Estrogen replacement reverses endothelial dysfunction in postmenopausal women. American Journal of Medicine 1998 104 552-558. (doi:10.1016/S0002-9343(98)00117-X)
38. Lieberman EH, Gerhard MD & Uehata A. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Annals of Internal Medicine 1994 121 936-941. (Pubitemid 24370856)
39. Hodis HN, Mack WJ & Lobo RA. Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine 2001 135 939-953. (Pubitemid 33131615)